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Background: Metabolic syndrome (MetS) refers to a cluster of cardiovascular risk factors including hyperglycemia,
dyslipidemia, abdominal obesity and hypertension. An effective detection of MetS not only reflects the prediction
risk of diabetes mellitus and cardiovascular diseases but also helps to plan for management strategy which could
reduce the healthcare burden of the society. This study aimed to compare the use of hemoglobin A1c (HbA1c) to
fasting plasma glucose (FPG) as the hyperglycemic component in MetS diagnosis.
Methods: Waist circumference, blood pressure, blood triglyceride, high-density lipoprotein (HDL)-cholesterol, FPG,
and HbA1c were examined in 120 Hong Kong Chinese adults with MetS and 120 without MetS. After reviewing the
subject basal characteristics, 11 of them were found with undiagnosed diabetes (FPG ≧7.0 mmol/L) and were
excluded for further analysis.
Results: The most prevalent MetS components among the included subjects were elevated systolic blood pressure
and central obesity. Significant correlation relationships existed between FPG and HbA1c in both subject pools
diagnosed with and without MetS (p < 0.001). The diagnostic rate of MetS using HbA1c was compared to FPG by
the receiver operating characteristics (ROC) analysis which suggested an area under curve of 0.807 (95% CI: 0.727 to
0.887). The agreement was 90.7% in MetS-positive group with increased FPG as one of the criterion co-existed with
elevated HbA1c. If including HbA1c as an additional criterion to FPG in the MetS diagnosis, 30 more participants in
MetS-negative group would be MetS-positive leading to an increase in detection rate. Furthermore, 47 subjects
(38 from MetS-positive group and 9 from MetS-negative group) were found having HbA1c ≧6.5%, who would have
been diagnosed with diabetes based on the diagnostic criteria implemented by the Expert Group in 2009.
Conclusion: These findings suggest that HbA1c enhances the detection of hyperglycemia for the diagnosis of MetS.Background
Metabolic syndrome (MetS) refers to a cluster of meta-
bolic abnormalities including hyperglycemia, dyslipid-
emia, abdominal obesity and high blood pressure, which
is closely associated with the development of type 2 dia-
betes mellitus and cardiovascular diseases. The incidence
of diabetes and cardiovascular diseases has been reported
to be considerably increased in individuals with MetS
[1,2]. The risks of having heart disease, stroke, and dia-
betes have been shown to be increased by 1.5- to 3-fold
in people with MetS when compared to people without
MetS [3].* Correspondence: parco.siu@polyu.edu.hk
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unless otherwise stated.The occurrence of MetS is suggested to be affected by
many factors including genetics, stress, improper diet,
lack of physical activity, weight gain, increased alcohol
consumption, smoking, and inadequate sleep [4-10]. The
prevalence of MetS worldwide is approximately 20-30% in
general population and it is apparently on an increasing
trend. In the United States, the prevalence was 23.7%
which was similar to Europe and the percentage appeared
to be higher in population with advanced age [11]. In Asia,
the prevalence of MetS reported in different countries
were quite varied ranged from 21.9% in Thailand to 49.4%
in Malaysia [11,12]. The prevalence of MetS in Korea has
been shown to be significantly increased from 24.9% in
1998 to 31.3% in 2007 [12]. The prevalence of MetS in
mainland China and Hong Kong has been reported to be
29.3% in middle-aged Chinese men and 26.8% in Hong
Kong professional drivers [10,13]. A cohort study hasl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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indeed been increased from 9.6% in 1990s to 23% in
2000s in Hong Kong [14]. These figures indisputably
illustrated that MetS has been a global alarming public
health concern [15].
Intervention applied to individual with MetS offers an
early effective approach to prevent or delay the onset of
the associated chronic diseases including diabetes and
cardiovascular diseases. From a public health point of
view, appropriate management of MetS through lifestyle
modification such as dietary management and physical
exercise has a significant healthcare value to combat
with the growing prevalence of diabetes and cardiovas-
cular diseases [1,5,8-10,16,17]. Successful reversal of
the MetS conditions should have considerable impact
to diminish the number of emerging cases of diabetes
and cardiovascular diseases, which would largely lessen
the future healthcare expenses associated with diabetes
and cardiovascular diseases [18]. Thus, effective detection
of MetS not only reflects the prediction risk of diabetes
and cardiovascular diseases but also helps to plan for
management strategy which could reduce the healthcare
burden of the society. In this study, we aimed to examine
the supplementary use of hemoglobin A1c (HbA1c)
as the hyperglycemic component for MetS diagnosis.
HbA1c was examined because of its higher reproduci-




In this case-control study, 240 Hong Kong Chinese
adults (120 diagnosed with MetS and 120 without MetS)
aged 30 to 80 years from the community were voluntarily
recruited. Informed consent was obtained from all sub-
jects. All the experimental procedures received human
research ethics approval from The Hong Kong Polytechnic
University.
MetS parameters and blood biochemistry
Cardiovascular measurements including systolic and
diastolic blood pressure were examined by an electronic
blood pressure monitor (Accutorr Plus, Datascope). Blood
pressure measurement was determined on the right arm
after 5-min seated rest. Systolic and diastolic blood
pressure was obtained over the brachial artery region
with the arm supported at heart level using appropriate
sized cuff. The average of two measurements taken with
a 1-min interval between them was recorded for ana-
lysis. Waist circumference was measured midway be-
tween the lowest rib and the superior border of the iliac
crest using an inelastic measuring tape on the bare skin
and recorded to the nearest 0.1 cm. The tape was snugged
horizontally around the abdomen passing across the navelwithout causing compression on the skin. Measurement
was performed at the end of normal expiration. Bio-
chemical measurements were performed on fasting
plasma harvested from venous blood samples collected
after an overnight (a minimum of 10 hours) fast. Plasma
glucose, triglycerides, and HDL-cholesterol concentra-
tions were measured by an accredited medical labora-
tory by commercial test kit methods using an automatic
clinical chemistry analyzer (Architect CI8200, Abbott
Diagnostics).
Definition of Metabolic Syndrome (MetS)
Metabolic syndrome (MetS) was diagnosed according
to the guideline of the United States National Cholesterol
Education Program (NCEP) Expert Panel Adult Treat-
ment Panel (ATP) III criteria, in which an individual
diagnosed with MetS has three or more of following
characteristics: 1) central obesity (waist circumference
exceeds 90 cm or 80 cm for Asian male and female,
respectively), 2) hypertension (systolic pressure equals
or exceed 130 mmHg or diastolic pressure equals or
exceeds 85 mmHg), 3) elevated blood glucose (fasting glu-
cose level equals or exceeds 5.6 mmol/L [100 mg/dL]), 4)
elevated plasma triglycerides (level equals or exceeds
1.70 mmol/L [150 mg/dL]), and 5) low level of high-
density lipoprotein-cholesterol (HDL-C; level equals
or is less than 40 mg/dL for male and 50 mg/dL for
female) [19].
Measurement of hemoglobin A1c (HbA1c)
HbA1c was measured by ion exchange HPLC method
using the VARIANT II Hemoglobin A1c Program manu-
factured by Bio-Rad Laboratories. The method is trace-
able to the reference methods of both the National
Glycohemoglobin Standardization Program (NGSP) and
the International Federation of Clinical Chemistry and
Laboratory Medicine (IFCC). Also, it has been certified
by the NGSP as having documented traceablility to the
Diabetes Control and Complications Trial (DCCT) ref-
erence method (American Diabetes Association). The
VARIANT II Hemoglobin A1c Program is based on the
principles on ion exchange high performance liquid
chromatography (HPLC) method by a programmed
buffer gradient, of increasing ionic strength, to the cart-
ridge where the hemoglobins are separated based on
their specific ionic interactions with the cartridge ma-
terial. The separated hemoglobin then passed through
the flow cell of the filter photometer, where the changes
in the absorbance at 415 nm were measured. An
additional filter at 690 nm was used for background
absorbance correction. A chromatogram was generated
with the HbA1c peak shaded and the percentage of
HbA1c was reported in SI percent units (HbA1c/total
Hb). In order to convert the SI percent units to the
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a consensus statement issued by the working group
including the ADA, IDF, European Association for the
Study of Diabetes and IFCC in 2007, the equation of
IFCC: HbA1c(mmol/mol) = [HbA1c(%)–2.15] × 10.929
was adopted (American Diabetes Association). The ana-
lysis was performed in four consecutive days and each
blood sample was analyzed twice and the mean results
were obtained. The maximum within run percentage of
coefficient of variation (%CV) using two lyophilized whole
blood samples for non-diabetic range (4.7–5.9%) and dia-
betic range (8.7-11.1%) were 2.8% and 1.7%, respectively.
The across run%CV using the same lyophilized whole
blood samples were 3.6% and 3.8%, respectively.
Data analysis
Statistical analyses were performed by using Statistical
Package for Social Science (SPSS), version 17.0 for
windows. Data are expressed as mean ± standard devi-
ation. Independent t-test or Mann-Whitney U test were
used to compare the difference between groups. The
relationship between HbA1c and fasting plasma glucose
(FPG) across groups was analyzed by Pearson correl-
ation or Spearman correlation. P-value of <0.05 would
be considered statistically significant. Chi-square by
McNemar test was used to compare the use of HbA1c
to FPG to detect MetS. The diagnostic property of using
HbA1c and FPG for MetS was evaluated by receiver
operating characteristics (ROC) curve with the 95%
confidence intervals.
Results
Among the 240 subjects examined, 120 were diagnosed
with metabolic syndrome (MetS-positive) and 120 wereTable 1 Basal characteristics of the subjects
All
n = 229
Age (years) 58.7 ± 10.5
WC (cm) 85.9 ± 10.6
SBP (mmHg) 139.5 ± 20.3
DBP (mmHg) 79.4 ± 11.1
FPG (mmol/L) 5.3 ± 0.6
TG (mmol/L) 1.5 ± 0.7
HDL (mmol/L) 1.4 ± 0.3
HbA1c (%) 6.1 ± 0.5
Correlation coefficient between HbA1c and FPG 0.593, P < 0.001
Note: SBP, systolic blood pressure; DBP, diastolic blood pressure; WC, waist circumfe
plasma glucose; HbA1c, haemoglobin A1c; data are expressed as mean ± standard d
line of the United States National Cholesterol Education Program (NCEP) Expert Pan
with MetS has three or more of following characteristics: 1) central obesity (waist ci
2) hypertension (systolic pressure equals or exceed 130 mmHg or diastolic pressure
equals or exceeds 5.6 mmol/L [100 mg/dL]), 4) elevated plasma triglycerides (level e
lipoprotein-cholesterol (HDL-C; level equals or is less than 40 mg/dL for male and 5not having metabolic syndrome (MetS-negative) based
on the NCEP diagnostic guideline. Of note, 11 MetS-
positive subjects (9 male and 2 female) were found having
fast plasma glucose (FPG) ≧7 mmol/L, which were classi-
fied as diabetic according to the consensus statement in
2009 [20] and were thus excluded in this study. In sum,
data obtained from 109 MetS-positive subjects (51 male
and 58 female) and 120 MetS-negative subjects (60 male
and 60 female) were included in our analyses. The basal
characteristics of these 229 subjects are shown in Table 1.
The prevalence of individual MetS components and
HbA1c is summarized in Table 2. Among the 229 sub-
jects, the most frequently met MetS criteria were systolic
blood pressure (SBP) (n =161, 70.3%) and waist circum-
ference (n =125, 54.6%) (Table 2). The prevalence of
hyperglycemia defined as elevated FPG (defined as FPG
≧5.6 mmol/L [100 mg/dL]) was found in 65 subjects
(28.4%) whereas elevated HbA1c (defined as HbA1c
≧5.7%) was found in 194 subjects (84.7%) (Table 2). This
observation demonstrated that a large portion of our ex-
amined subjects (i.e., 84.7% - 28.4% =56.3%) had normal
level of FPG but elevated level of HbA1c. If using
HbA1c as a hyperglycemic criterion in MetS definition,
the number of subjects with different number of compo-
nents present when using FPG criterion or HbA1c cri-
terion was summarized in Table 3. The percentage of
MetS-positive subjects would be increased from 47.6%
(109 out of 229 subjects) by using FPG as the criterion
to 60.7% (139 out of 229 subjects) by using HbA1c as
the criterion.
As shown in the cross-tabulation table between FPG
and HbA1c (Table 4), only 55.7% of subjects (59/109)
had FPG ≧5.6 mmol/L as one of the criterion in MetS-





59.1 ± 10.6 58.3 ± 10.4 0.556
92.8 ± 8.2 79.6 ± 8.3 <0.001
145.3 ± 17.7 134.1 ± 21.1 <0.001
82.5 ± 10.9 76.7 ± 10.6 <0.001
5.6 ± 0.6 5.0 ± 0.4 <0.001
1.9 ± 0.7 1.2 ± 0.5 <0.001
1.2 ± 0.3 1.6 ± 0.3 <0.001
6.3 ± 0.6 5.9 ± 0.4 <0.001
0.569, P < 0.001 0.397, P < 0.001
rence; HDL, high-density lipoprotein cholesterol; TG, triglyceride; FPG, fasting
eviation. Metabolic syndrome (MetS) was diagnosed according to the guide-
el Adult Treatment Panel (ATP) III criteria, in which an individual diagnosed
rcumference exceeds 90 cm or 80 cm for Asian male and female, respectively),
equals or exceeds 85 mmHg), 3) elevated blood glucose (fasting glucose level
quals or exceeds 1.70 mmol/L [150 mg/dL]), and 5) low level of high-density
0 mg/dL for female) [19].
Table 2 Prevalence of individual MetS components and
HbA1c
All MetS-positive MetS-negative
Number (%) 229 (100%) 109 (100%) 120 (100%)
WC 125 (54.6%) 101 (92.7%) 24 (20.0%)
SBP 161 (70.3%) 94 (86.2%) 67 (55.8%)
DBP 112 (48.9%) 67 (61.5%) 45 (37.5%)
FPG 65 (28.4%) 59 (54.1%) 6 (5.0%)
TG 90 (39.3%) 68 (62.4%) 22 (18.3%)
HDL 70 (30.6%) 61 (56.0%) 9 (7.5%)
HbA1c 194 (84.7%) 99 (90.8%) 95 (79.2%)
Note: SBP, systolic blood pressure; DBP, diastolic blood pressure; WC, waist
circumference; HDL, high-density lipoprotein cholesterol; TG, triglyceride; FPG,
fasting plasma glucose; HbA1c, haemoglobin A1c. Data are expressed as
frequency count (%). Metabolic syndrome (MetS) was diagnosed according
to the guideline of the United States National Cholesterol Education Program
(NCEP) Expert Panel Adult Treatment Panel (ATP) III criteria, in which an individual
diagnosed with MetS has three or more of following characteristics: 1) WC
exceeds 90 cm or 80 cm for Asian male and female, respectively, 2) SBP equals or
exceed 130 mmHg or DBP equals or exceeds 85 mmHg, 3) FPG equals or exceeds
5.6 mmol/L [100 mg/dL], 4) TG equals or exceeds 1.70 mmol/L [150 mg/dL]), and
5) HDL-C equals or is less than 40 mg/dL for male and 50 mg/dL for female) [19].
Elevated HbA1c is defined as HbA1c ≧5.7%.
Table 4 Cross-tabulation contingency table showing FPG
and HbA1c in MetS-positive and MetS-negative groups
Fasting plasma glucose
Yes No Total
MetS-positive group HbA1c Yes 58 41 99
No 1 9 10
Total 59 50 109
MetS-negative group HbA1c Yes 5 90 95
No 1 24 25
Total 6 114 120
Yes: Fasting plasma glucose or HbA1c above the cutoff and met with
MetS criterion.
No: Fasting plasma glucose or HbA1c below the cutoff for MetS criterion.
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creased FPG or HbA1c, and 53.2% of subjects (58/109)
had both increased FPG and HbA1c. In MetS-negative
group, only 5% of subjects (6/120) had FPG ≧5.6 mmol/L
but 79.2% of subjects (95/120) had HbA1c ≧5.7%, 80% of
subjects (96/120) had either increased FPG or HbA1c, and
only 4.2% of subjects (5/120) had both increased FPG
and HbA1c. The use of HbA1c as a criterion for MetS
detection was analyzed by McNemar test in which the
Chi-square (χ2) in MetS-positive group was 38.1 with
significance at α = 0.05 and the phi coefficient (ϕ) was
0.591 (p < 0.001), representing a moderate relationship.
A stronger relationship was observed in MetS-negative
group, in which the Chi-square (χ2) was 87.0 and the
phi coefficient (ϕ) was 0.851 (p < 0.001). These results
demonstrated that the proportion of subjects to be de-
tected with MetS was increased by using HbA1c criter-
ion when compared to FPG criterion.
Our intra-class correlation analysis indicated that the
Cronbach’s alpha (α) between FPG and HbA1c was mod-
erately high in MetS-positive group, α =0.725 (95% CI:
0.599 to 0.812, p < 0.001) and in MetS-negative group,
α =0.576 (95% CI: 0.391 to 0.704, p < 0.001). The percentageTable 3 Number of subjects with different number of compon
HbA1c as the hyperglycemic criterion
Number of MetS component present 0 1 2
FPG as criterion n 32 45 43
(%) (14.0) (19.7) (18.8
HbA1c as criterion n 10 40 40
(%) (4.4) (17.5) (17.5of agreement was 90.7% with the kappa coefficient, κ =0.616
between FPG and HbA1c in those 65 subjects with FPG
≧5.6 mmol/L. However, the percentage of agreement be-
tween FPG and HbA1c in MetS-positive group (n =109)
was only 61.5% (κ =0.079). This result might be due to the
large discrepancy between the prevalence of corresponding
criterion in the group (i.e., 59 out of 109 MetS-positive sub-
jects met FPG criterion but 99 of them met the HbA1c
criterion).
The diagnostic property of HbA1c at the level of
≧5.7% for MetS diagnosis was evaluated by receiver op-
erating characteristics (ROC) analysis. The area under
ROC curve of HbA1c for detecting subjects with MetS
relative to FPG was 0.807 (95% CI: 0.727 to 0.887),
which yielded a sensitivity level of 98.3%, specificity of
18%, positive predictive value (PPV) of 58.6%, and a
negative predictive value (NPV) of 90.0%. When HbA1c
cutoff was used to test the presence of MetS, it yielded a
sensitivity of 90.8%, specificity of 20.8%, PPV of 51.0%,
and NPV of 71.4%. Similar diagnostic properties as indi-
cated by the areas under ROC curve were obtained by
using FPG and HbA1c in MetS-positive (0.778 for FPG
and 0.736 for HbA1c).
According to the diagnostic criteria of the consensus
statement released by the working group report of Inter-
national Expert Committee in 2009 [20], individuals who
have FPG less than 5.6 mmol/L or HbA1c less than 5.7%
are defined to be normal. FPG between 5.6 to 6.9 mmol/L
or HbA1c between 5.7-6.4% are at pre-diabetic state
and with FPG above 7.0 mmol/L or HbA1c ≧6.5% areents present when using fasting plasma glucose (FPG) or
3 4 5 Met ≧3 components (MetS-positive)
56 43 10 109
) (24.5) (18.8) (4.4)
59 59 21 139
) (25.8) (25.8) (9.2)
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study, 11 diabetic subjects with FPG ≧7.0 mmol/L were
excluded. By considering the level of HbA1c, 47 sub-
jects would have been diagnosed with diabetes (38 from
MetS-positive group and 9 from MetS-negative group)
which were mid-diagnosed based on the measurement
of FPG.
Discussion
In the present study, the prevalence of metabolic syn-
drome (MetS) was observed to be increased by 13% after
adopting hemoglobin A1c (HbA1c) as the hyperglycemic
criterion in the diagnosis of MetS when compared to the
use of fasting plasma glucose (FPG) with a good agree-
ment (90.7%, κ = 0.62). These results are in agreement
with previous studies reported the increased prevalence
of MetS when adopting HbA1c instead of FPG in MetS
diagnosis [21,22]. Nonetheless, it is worth to note that
there were also controversial results demonstrated that
the use of HbA1c might result in a decreased prevalence
of MetS. The prevalence of MetS was reported to be
decreased by 4-7% in the study that examined the US
National Health and Nutrition Examination Survey data
and a Korean cross-sectional study [23,24]. According
to our present data, thirty more participants would be
diagnosed with MetS after including HbA1c as a supple-
mentary hyperglycemic criterion. Of note, these thirty
participants included 10 participants aged below or
equal to sixty years and 20 participants aged above sixty
years. If categorized by gender, there were 19 men and
11 women among these thirty participants. Our coarse
observations suggested that the adoption of HbA1c
hyperglycemic criterion seemed to be more responsive
in the male participants of age above sixty. Nevertheless,
the observed discrepancy between our present findings
and previous studies might be attributed to the differ-
ences in study design (i.e., case control study vs. ran-
domized study), age and gender distribution of the
subjects, sample size, ethnicity, and pre-analytical or
analytical factors which might have affected the mea-
surements of HbA1c and FPG.
Among the Hong Kong Chinese participants in this
study, it was observed that the most prevalent MetS
components observed were high blood pressure and
central obesity, which were similar to the previous ob-
servations reported by studies conducted in Italy and
Korea [22,23]. The incidence of hypertension appeared
to be higher in the participants aged above 60 particu-
larly those male. It was not surprising that blood pres-
sure was elevated with advanced age due to the fact that
arterial stiffness is increased and insulin resistance is
common in elderly which generally impair the vaso-
dilating function of blood vessels. Besides, Kim and col-
leagues have demonstrated that the brachial-ankle pulsewave velocity (baPWV), a measurement of arterial stiff-
ness, in male was markedly higher than that in female,
which might help to explain the currently observed
higher incidence of high blood pressure in men com-
pared to female [23]. In regard to the prevalence of
central obesity as measured by waist circumference, it
was observed to be more commonly seen in our female
participants. It has been proposed that neuro-hormonal
dysregulation characterized by the activation of stress-
related hormones and age-related decline in sex hor-
mone and growth hormone especially after menopause
might lead to increase in deposition of visceral adipos-
ity causing insulin resistance and thus enhances the
development of MetS [25]. Indeed, ample amount of
evidence have illustrated that the risk factors of the
development of MetS were inter-correlated and insulin
resistance plays an important role in the pathophysio-
logic process of the development of MetS. Therefore,
once insulin resistance occurs, accumulation of fatty
acids might follow which results in the consequence of
accelerating other risk factors including hypertriglyc-
eridemia, reduced high-density lipoprotein cholesterol,
and hyperglycemia [26].
In the present study, the correlations observed be-
tween HbA1c and FPG in all participants and MetS-
positive group were moderate, which are consistent
with the previous reports [27]. The observed moderate
degree of correlation relationship between HbA1c and
FPG might be attributed to the differences in the amount
of glycosylation that is known to be varied from individual-
to-individual [28]. Other possible explanations included
change in intra-erythrocyte environment, difference in
degree of glycemic control, heterogeneity in the lifespan
of red cell, and racial difference [28-30]. Besides, rather
high variability of fasting plasma glucose might also re-
sult in moderate correlations observed between HbA1c
and fasting plasma glucose [31].
Regarding the diagnostic property comparison of
HbA1c to fasting plasma glucose in the detection of
MetS, the area under the ROC curve in the present
study was 0.807 (95% CI: 0.727 to 0.887) which was
found to be similar to previous reports that demon-
strated moderate-to-high property by adopting HbA1c
hyperglycemic criterion, in which the reported area
under ROC curve was 0.678 in Succurro et al. study
and 0.895 in van’t Riet et al. study [22,27]. Based on
our results, the areas under the ROC curves by using
fasting plasma glucose and HbA1c in MetS diagnosis
were 0.778 and 0.736, respectively, suggesting that
similar diagnostic values were obtained from fasting
plasma glucose and HbA1c for MetS detection. None-
theless, although HbA1c seemed not offering a higher
diagnostic value when compared to fasting plasma
glucose, we interpreted that the measurement of HbA1c
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tection of hyperglycemic episode in MetS detection. Ac-
cording to the consensus statement of the American
Diabetes Association in 2010 [32], an individual having
HbA1c at range of 5.7% to 6.4% would be classified as
pre-diabetic whereas HbA1c greater than 6.4% would be
diagnosed with diabetes mellitus. Of note, 11 participants
in MetS-positive group were found to have fasting plasma
glucose greater than 7.0 mmol/L at the beginning of this
study and these subjects were excluded for data analyses.
Thus theoretically, there should have no known diabetic
cases in the subject pool being examined in the present
study (in which the diagnosis of diabetes is based on
fasting plasma glucose). However, we observed that 47 of
our included 229 participants (21%) were found having
HbA1c level greater than 6.4%, who would have been
diagnosed with diabetes mellitus according to the criteria
of the American Diabetes Association [32]. These hidden
diabetic individuals, whose fasting plasma glucose was
normal but HbA1c was elevated, would not be revealed if
blood glucose was solely used as the hyperglycemic criter-
ion in the detection process.
Metabolic syndrome (MetS) does not refer to the
diagnosis of a disease status but is rather taken as a
“sign” to alert individuals who have metabolic abnor-
malities which are closely associated with the develop-
ment of diabetes mellitus and cardiovascular diseases
[26]. Most importantly, the risk factors and diagnostic
components of MetS are readily to be improved and
reversed by lifestyle modification (i.e., diet and exer-
cise) in order to delay or prevent the onset of diabetes
mellitus and cardiovascular diseases. According to the
findings of the present study, HbA1c, which is the
glycated form of hemoglobin that reflects the average
glucose content in the blood in previous two to three
months, together with fasting plasma glucose appeared
to be an appropriate hyperglycemic criterion in identi-
fying MetS with an improved detection and in revealing
hidden diabetic cases that failed to be detected by solely
fasting plasma glucose. Notably, the present study might
have some limitations. First, the samples were not ran-
domly obtained from the entire population but from a
volunteer-based manner with our adopted case-control
study design, which might have selection bias and reduc-
tion of generalizability. Besides, similar to the cross-
sectional epidemiologic studies, the present study did not
have further continuous evaluations in tracking the devel-
opment of diseases such as diabetes and cardiovascular
diseases. In conclusion, the results of this study support
the feasibility of the use of hemoglobin A1c (HbA1c)
together with fasting plasma glucose (FPG) as the hyper-
glycemic criteria in the detection of MetS. Although
similar diagnostic properties were observed by using
HbA1c and fasting plasma glucose in the diagnosis ofMetS, the measurement of HbA1c provides additional
value in revealing the hidden diabetic cases which were
not detected with the sole examination of fasting plasma
glucose.
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